All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results ConPlas-19, 2020 0.56 [0.20; 1.57]
DAWN-Plasma, 2021 0.61 [0.24; 1.55]
NCT04397757, 2021 0.47 [0.04; 5.45]
Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
0.82 [0.42 ; 1.61 ] ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021 4 24% 1,072 moderate not evaluable death D28detailed results Abdulamir, 2021 1.00 [0.20; 5.12]
Abuhasira, 2021 0.72 [0.23; 2.24]
AlQahtani, 2020 0.47 [0.04; 5.69]
ASCOT, 2021 0.60 [0.06; 5.99]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.12 [0.86; 1.46]
ConPlas-19, 2020 0.49 [0.20; 1.19]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
FACCT Trial, 2021 0.69 [0.28; 1.68]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
Horby, 2021 1.01 [0.93; 1.10]
Jamaati, 2021 1.19 [0.38; 3.72]
Kirenga, 2021 1.25 [0.46; 3.39]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Mahajan, 2021 1.23 [0.34; 4.42]
Menichetti, 2021 0.75 [0.37; 1.53]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
Rutgers, 2021 0.59 [0.33; 1.06]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shahbaznejad, 2020 2.21 [0.07; 67.87]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shu, 2020 0.38 [0.02; 8.14]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
0.96 [0.92 ; 1.00 ] Abdulamir, 2021, Abuhasira, 2021, AlQahtani, 2020, ASCOT, 2021, Co-CLARITY, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, COPLA-II trial, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, FACCT Trial, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Horby, 2021, Jamaati, 2021, Kirenga, 2021, Krolewiecki, 2020, Li, 2020, LIFESAVER, 2021, Mahajan, 2021, Menichetti, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, Pouladzadeh, 2021, Raman, 2021, RAPID (Sholzberg), 2021, RECOVER, 2021, RECOVERY, 2020, RECOVERY, 2022, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, Rutgers, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shahbaznejad, 2020, Shashi Bhushan, 2021, Shu, 2020, SOLIDARITY (WHO study) HCQ, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021 60 10% 84,642 moderate critical death or transfer to ICUdetailed results RAPID (Sholzberg), 2021 0.70 [0.44; 1.12]
RECOVERY, 2020 1.09 [0.99; 1.20]
0.93 [0.61 ; 1.41 ] RAPID (Sholzberg), 2021, RECOVERY, 2020 2 69% 5,301 moderate not evaluable deathsdetailed results Abd-Elsalam, 2020 1.21 [0.36; 4.12]
Abdulamir, 2021 1.00 [0.20; 5.12]
AlQahtani, 2020 0.47 [0.04; 5.69]
ASCOT, 2021 0.60 [0.06; 5.99]
Cao, 2020 0.71 [0.36; 1.40]
CAPSID, 2021 0.84 [0.28; 2.50]
Chen, 2020 0.56 [0.01; 30.20]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59]
CONFIDENT, 2020 0.84 [0.52; 1.37]
ConPlas-19, 2020 0.46 [0.19; 1.15]
COP-COVID-19, 2021 0.96 [0.36; 2.56]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Dabbous HM, 2020 0.51 [0.02; 15.41]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Entrenas (Pilot Calcifediol), 2020 0.12 [0.01; 2.79]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
FACCT Trial, 2021 0.96 [0.44; 2.08]
Fu, 2020 1.00 [0.02; 51.66]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
GRECCO-19, 2020 0.21 [0.02; 1.97]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
Hashim A, 2020 0.48 [0.11; 1.99]
Holm K, 2021 0.49 [0.08; 2.89]
Horby, 2021 1.01 [0.93; 1.10]
Jamaati, 2021 1.19 [0.38; 3.72]
Khamis, 2020 0.83 [0.23; 2.96]
Kirenga, 2021 1.25 [0.46; 3.39]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Lou (FAVIPIRAVIR), 2020 1.12 [0.02; 62.74]
Lou Y, 2020 1.00 [0.02; 55.80]
Mahajan, 2021 1.23 [0.34; 4.42]
Menichetti, 2021 0.75 [0.37; 1.53]
NCT04385199, 2021 0.75 [0.15; 3.77]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04542694, 2020 1.00 [0.02; 50.90]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
Rasheed, 2020 0.13 [0.01; 1.09]
RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY, 2020 1.03 [0.91; 1.17]
RECOVERY, 2021 0.85 [0.76; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
Rutgers, 2021 0.62 [0.36; 1.07]
Sadeghi , 2020 0.56 [0.12; 2.56]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekhavati, 2020 0.49 [0.02; 14.80]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shu, 2020 0.38 [0.02; 8.14]
Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55]
SOLIDARITY (lopi/rito), 2020 1.00 [0.79; 1.26]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Udwadia, 2020 0.50 [0.02; 15.03]
Veiga, 2021 2.70 [0.92; 7.92]
Yakoot, 2020 0.38 [0.07; 2.08]
0.94 [0.91 ; 0.97 ] Abd-Elsalam, 2020, Abdulamir, 2021, AlQahtani, 2020, ASCOT, 2021, Cao, 2020, CAPSID, 2021, Chen, 2020, Co-CLARITY, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, COP-COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, CP-COVID-19, 2021, Dabbous HM, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, DEXA-COVID19, 2020, Entrenas (Pilot Calcifediol), 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, FACCT Trial, 2021, Fu, 2020, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hashim A, 2020, Holm K, 2021, Horby, 2021, Jamaati, 2021, Khamis, 2020, Kirenga, 2021, Krolewiecki, 2020, Li, 2020, LIFESAVER, 2021, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Mahajan, 2021, Menichetti, 2021, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04523831 (Mahmud), 2020, NCT04528368, 2021, NCT04542694, 2020, NCT04577534 (COVIDSTORM), 0, NO COVID-19 (Lyngbakken), 2020, NOR-Solidarity (hydroxychloroquine), 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, RAPID (Sholzberg), 2021, Rasheed, 2020, RCT-TCZ-COVID-19, 2021, RECOVER, 2021, RECOVERY, 2020, RECOVERY, 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, Rutgers, 2021, Sadeghi , 2020, Sakoulas, 2020, Sekhavati, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Soin AS (COVINTOC), 2021, SOLIDARITY (lopi/rito), 2020, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Steroids-SARI, 2020, Tabarsi, 2020, Talaschian, 2021, Udwadia, 2020, Veiga, 2021, Yakoot, 2020 106 6% 117,004 moderate critical deaths (time to event analysis only)detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
Rutgers, 2021 0.62 [0.36; 1.07]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Talaschian, 2021 1.25 [0.30; 5.14]
0.97 [0.91 ; 1.03 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NOR-Solidarity (hydroxychloroquine), 2021, RECOVERY, 2020, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Rutgers, 2021, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Talaschian, 2021 19 20% 40,923 moderate low clinical deteriorationdetailed results CAPSID, 2021 0.63 [0.29; 1.40]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.92 [0.61; 1.38]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58]
ConPlas-19, 2020 1.00 [0.65; 1.53]
CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
ELACOI (Standard of care), 2020 0.86 [0.06; 11.36]
GRECCO-19, 2020 0.11 [0.01; 1.08]
Hashim A, 2020 0.40 [0.10; 1.63]
Kirenga, 2021 0.91 [0.38; 2.17]
Li T, 2020 0.48 [0.01; 27.44]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
RAPID (Sholzberg), 2021 0.69 [0.43; 1.10]
RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86]
Shu, 2020 0.27 [0.01; 5.58]
Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77]
0.78 [0.66 ; 0.91 ] CAPSID, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, ConPlas-19, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, GRECCO-19, 2020, Hashim A, 2020, Kirenga, 2021, Li T, 2020, NCT04523831 (Mahmud), 2020, RAPID (Sholzberg), 2021, RCT-TCZ-COVID-19, 2021, Shu, 2020, Soin AS (COVINTOC), 2021 19 0% 3,191 moderate low clinical improvementdetailed results AVIFAVIR, 2020 0.53 [0.13; 2.19]
Cao, 2020 1.31 [0.94; 1.83]
CAPSID, 2021 1.58 [0.71; 3.49]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Dongsheng Wang, 2020 2.37 [0.40; 13.96]
Ghandehari, 2020 1.31 [1.00; 1.71]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
Li, 2020 1.40 [0.79; 2.49]
Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
NCT04542694, 2020 2.10 [1.04; 4.24]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Udwadia, 2020 1.75 [1.10; 2.79]
1.26 [1.07 ; 1.49 ] AVIFAVIR, 2020, Cao, 2020, CAPSID, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, ConPlas-19, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Dongsheng Wang, 2020, Ghandehari, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, Lou (FAVIPIRAVIR), 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pouladzadeh, 2021, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (tocilizumab), 2021, Ruzhentsova T, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Udwadia, 2020 24 59% 5,065 moderate low clinical improvement (14-day)detailed results AVIFAVIR, 2020 0.53 [0.13; 2.19]
Cao, 2020 1.94 [1.09; 3.48]
Chen, 2020 0.56 [0.13; 2.48]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
Li, 2020 2.27 [0.90; 5.72]
Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
Lou Y, 2020 1.50 [0.26; 8.82]
Pandit, 2021 8.77 [0.94; 81.67]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
Ruzhentsova T, 2020 1.28 [1.05; 1.56]
Sadeghi , 2020 3.63 [1.02; 12.93]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
1.13 [0.91 ; 1.40 ] AVIFAVIR, 2020, Cao, 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Pandit, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Ruzhentsova T, 2020, Sadeghi , 2020, Shashi Bhushan, 2021, Shu, 2020 19 56% 4,445 moderate low clinical improvement (21-day)detailed results Li T, 2020 2.09 [0.04; 119.96]
2.09 [0.04 ; 119.96 ] Li T, 2020 1 0% 18 NA not evaluable clinical improvement (28-day)detailed results Abuhasira, 2021 1.70 [0.52; 5.49]
Cao, 2020 1.59 [0.84; 3.03]
COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04]
GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
Li, 2020 1.42 [0.65; 3.10]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Ruzhentsova T, 2020 1.11 [0.96; 1.29]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
Udwadia, 2020 1.75 [1.10; 2.79]
1.30 [1.03 ; 1.64 ] Abuhasira, 2021, Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, Pouladzadeh, 2021, Ruzhentsova T, 2020, Sekine (PLACOVID), 2021, Shu, 2020, Udwadia, 2020 11 59% 2,126 moderate critical clinical improvement (7-day)detailed results Cao, 2020 3.16 [0.62; 16.06]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35]
COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
Li, 2020 0.98 [0.27; 3.58]
Lou Y, 2020 1.00 [0.05; 18.57]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
NCT04542694, 2020 2.10 [1.04; 4.24]
Ruzhentsova T, 2020 1.50 [1.02; 2.21]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
Shu, 2020 6.72 [1.50; 30.07]
1.39 [1.10 ; 1.75 ] Cao, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, Lou Y, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Shu, 2020 12 46% 2,828 moderate low clinical improvement (time to event analysis only)detailed results Abuhasira, 2021 1.22 [0.70; 2.14]
Cao, 2020 1.31 [0.94; 1.83]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
FACCT Trial, 2021 0.85 [0.62; 1.16]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
Li, 2020 1.40 [0.79; 2.49]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
Rahmani, 2020 3.41 [1.33; 8.73]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Udwadia, 2020 1.75 [1.10; 2.79]
1.31 [1.12 ; 1.53 ] Abuhasira, 2021, Cao, 2020, ConPlas-19, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, NCT04523831 (Mahmud), 2020, Rahmani, 2020, Ruzhentsova T, 2020, Udwadia, 2020 13 44% 2,162 moderate critical death or ventilationdetailed results COLCOVID, 2021 0.83 [0.67; 1.02]
CONCOR-1, 2021 1.16 [0.94; 1.43]
ConPlas-19, 2020 0.94 [0.86; 1.02]
CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
DAWN-Plasma, 2021 1.01 [0.64; 1.59]
Menichetti, 2021 0.88 [0.59; 1.32]
RAPID (Sholzberg), 2021 0.59 [0.34; 1.02]
RECOVERY, 2020 1.14 [1.03; 1.27]
RECOVERY, 2021 0.85 [0.78; 0.93]
RECOVERY, 2022 0.90 [0.81; 0.99]
RECOVERY (AZI, Horby), 2020 0.95 [0.87; 1.03]
RECOVERY (colchicine), 2021 1.02 [0.96; 1.09]
RECOVERY (plasma), 2021 0.99 [0.93; 1.05]
RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
Rutgers, 2021 0.65 [0.43; 0.99]
SOLIDARITY (remdesivir), 2020 0.97 [0.85; 1.10]
SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42]
Veiga, 2021 1.54 [0.65; 3.63]
0.95 [0.90 ; 1.00 ] COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, DAWN-Plasma, 2021, Menichetti, 2021, RAPID (Sholzberg), 2021, RECOVERY, 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, Rutgers, 2021, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Veiga, 2021 20 61% 65,446 moderate low hospital dischargedetailed results ConPlas-19, 2020 1.02 [0.82; 1.28]
DAWN-Plasma, 2021 1.06 [0.87; 1.30]
FACCT Trial, 2021 0.88 [0.64; 1.21]
Li T, 2020 10.00 [1.03; 97.50]
Rahmani, 2020 3.44 [0.64; 18.49]
RECOVERY, 2020 0.98 [0.91; 1.05]
RECOVERY (Aspirin), 2022 1.06 [1.02; 1.10]
RECOVERY (AZI, Horby), 2020 1.04 [0.98; 1.10]
RECOVERY (colchicine), 2021 0.98 [0.94; 1.03]
RECOVERY (plasma), 2021 0.99 [0.92; 1.07]
RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92]
Udwadia, 2020 1.41 [0.97; 2.03]
1.03 [0.98 ; 1.08 ] ConPlas-19, 2020, DAWN-Plasma, 2021, FACCT Trial, 2021, Li T, 2020, Rahmani, 2020, RECOVERY, 2020, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Udwadia, 2020 15 68% 62,544 moderate low mechanical ventilationdetailed results Abuhasira, 2021 1.62 [0.41; 6.39]
AlQahtani, 2020 0.67 [0.22; 2.02]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COPLA-II trial, 2020 0.58 [0.37; 0.92]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.70 [0.52; 0.95]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06]
GRECCO-19, 2020 0.17 [0.02; 1.48]
GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
Holm K, 2021 0.39 [0.01; 12.68]
Jamaati, 2021 1.38 [0.45; 4.20]
Li T, 2020 0.40 [0.04; 3.90]
Lou Y, 2020 2.11 [0.06; 70.98]
Mahajan, 2021 2.27 [0.39; 13.27]
NCT04397757, 2021 0.41 [0.13; 1.35]
Rahmani, 2020 0.29 [0.05; 1.56]
RAPID (Sholzberg), 2021 0.70 [0.32; 1.54]
RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69]
RECOVERY, 2022 0.87 [0.74; 1.02]
RECOVERY (AZI, Horby), 2020 0.92 [0.79; 1.07]
RECOVERY (colchicine), 2021 1.04 [0.93; 1.16]
RECOVERY (plasma), 2021 0.98 [0.88; 1.09]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
Rutgers, 2021 0.65 [0.35; 1.24]
Sadeghi , 2020 0.37 [0.09; 1.58]
Sakoulas, 2020 0.19 [0.03; 1.11]
Sekhavati, 2020 0.16 [0.01; 3.19]
Shahbaznejad, 2020 2.24 [0.19; 25.88]
Shu, 2020 0.59 [0.02; 14.04]
Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38]
SOLIDARITY (remdesivir), 2020 1.04 [0.87; 1.23]
Tabarsi, 2020 1.49 [0.59; 3.78]
Udwadia, 2020 0.06 [0.01; 0.83]
Yakoot, 2020 0.38 [0.07; 2.08]
0.89 [0.82 ; 0.97 ] Abuhasira, 2021, AlQahtani, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, COPLA-II trial, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Holm K, 2021, Jamaati, 2021, Li T, 2020, Lou Y, 2020, Mahajan, 2021, NCT04397757, 2021, Rahmani, 2020, RAPID (Sholzberg), 2021, RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY dexamethasone, 2020, Rutgers, 2021, Sadeghi , 2020, Sakoulas, 2020, Sekhavati, 2020, Shahbaznejad, 2020, Shu, 2020, Soin AS (COVINTOC), 2021, SOLIDARITY (remdesivir), 2020, Tabarsi, 2020, Udwadia, 2020, Yakoot, 2020 38 27% 52,582 moderate critical mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
DAWN-Plasma, 2021 1.08 [0.65; 1.80]
Udwadia, 2020 0.06 [0.01; 0.83]
0.65 [0.25 ; 1.70 ] CP-COVID-19, 2021, DAWN-Plasma, 2021, Udwadia, 2020 3 60% 597 moderate not evaluable radiologic improvement (14-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
ELACOI (Standard of care), 2020 0.18 [0.01; 3.99]
Jamaati, 2021 4.89 [1.15; 20.79]
Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28]
Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88]
Tabarsi, 2020 2.33 [0.45; 12.00]
2.13 [1.30 ; 3.50 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Jamaati, 2021, Rashad (CLARI vs SoC), 2021, Rashad A (AZI vs SoC), 2021, Tabarsi, 2020 6 21% 584 moderate not evaluable radiologic improvement (7-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
ELACOI (Standard of care), 2020 0.08 [0.00; 1.71]
0.09 [0.01 ; 0.78 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020 2 0% 46 moderate not evaluable viral clearance detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
CP-COVID-19, 2021 1.12 [0.16; 7.84]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
NCT04542694, 2020 13.03 [2.96; 57.24]
Pandit, 2021 2.33 [0.55; 9.83]
Raman, 2021 36.42 [10.85; 122.18]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
Udwadia, 2020 1.37 [0.94; 1.98]
2.48 [1.47 ; 4.17 ] AVIFAVIR, 2020, CP-COVID-19, 2021, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Lou (FAVIPIRAVIR), 2020, NCT04542694, 2020, Pandit, 2021, Raman, 2021, Ruzhentsova T, 2020, Salman, 2020, Shashi Bhushan, 2021, Udwadia, 2020 13 72% 1,258 moderate low viral clearance (time to event analysis only)detailed results Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Udwadia, 2020 1.37 [0.94; 1.98]
1.32 [1.03 ; 1.69 ] Ruzhentsova T, 2020, Udwadia, 2020 2 0% 318 moderate not evaluable viral clearance by day 14detailed results AVIFAVIR, 2020 3.08 [0.62; 15.39]
Chen, 2020 1.42 [0.26; 7.76]
CP-COVID-19, 2021 1.51 [0.33; 6.94]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Kirenga, 2021 0.95 [0.76; 1.19]
Li T, 2020 1.00 [0.03; 34.67]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
Lou Y, 2020 0.12 [0.01; 2.86]
Pandit, 2021 10.23 [1.12; 93.35]
Raman, 2021 36.42 [10.85; 122.18]
Ruzhentsova T, 2020 0.99 [0.93; 1.06]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
0.97 [0.48 ; 1.93 ] AVIFAVIR, 2020, Chen, 2020, CP-COVID-19, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirenga, 2021, Li T, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Pandit, 2021, Raman, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021 13 93% 2,053 moderate low viral clearance by day 7detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
ELACOI (Standard of care), 2020 0.67 [0.10; 4.58]
Kirenga, 2021 0.87 [0.65; 1.16]
Lou Y, 2020 1.50 [0.26; 8.82]
Pandit, 2021 2.33 [0.55; 9.83]
Ruzhentsova T, 2020 1.05 [0.92; 1.20]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.27 [0.92 ; 1.76 ] AVIFAVIR, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirenga, 2021, Lou Y, 2020, Pandit, 2021, Ruzhentsova T, 2020, Salman, 2020, Shashi Bhushan, 2021 10 52% 837 moderate low ICU admissiondetailed results Abd-Elsalam, 2020 0.83 [0.35; 1.95]
Abuhasira, 2021 1.96 [0.51; 7.52]
COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Entrenas (Pilot Calcifediol), 2020 0.03 [0.00; 0.27]
FACCT Trial, 2021 1.42 [0.79; 2.55]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.87 [0.69; 1.10]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75]
Khamis, 2020 1.03 [0.35; 3.03]
Lou (FAVIPIRAVIR), 2020 5.43 [0.21; 139.89]
Lou Y, 2020 2.11 [0.06; 70.98]
Rahmani, 2020 0.37 [0.14; 1.00]
RAPID (Sholzberg), 2021 0.79 [0.48; 1.30]
Rutgers, 2021 0.96 [0.55; 1.68]
Sekhavati, 2020 0.25 [0.05; 1.28]
Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64]
Tabarsi, 2020 0.56 [0.18; 1.74]
Yakoot, 2020 0.38 [0.07; 2.08]
0.86 [0.69 ; 1.06 ] Abd-Elsalam, 2020, Abuhasira, 2021, COL-COVID (Pascual-Figal), 2021, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Entrenas (Pilot Calcifediol), 2020, FACCT Trial, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Khamis, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Rahmani, 2020, RAPID (Sholzberg), 2021, Rutgers, 2021, Sekhavati, 2020, Soin AS (COVINTOC), 2021, Tabarsi, 2020, Yakoot, 2020 20 22% 2,800 moderate low recoverydetailed results Abdulamir, 2021 1.00 [0.20; 5.12]
GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
Talaschian, 2021 0.64 [0.14; 2.92]
Yakoot, 2020 1.60 [1.00; 2.55]
1.17 [1.02 ; 1.35 ] Abdulamir, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Talaschian, 2021, Yakoot, 2020 5 0% 1,071 moderate not evaluable cardiac arrestdetailed results SOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49]
1.92 [0.35 ; 10.49 ] SOLIDARITY (WHO study) HCQ, 2020 1 0% 1,853 NA not evaluable related SAE (TRSAE)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11]
1.24 [0.50 ; 3.11 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable serious adverse eventsdetailed results Cao, 2020 0.52 [0.27; 1.01]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10]
COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77]
CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CONCOR-1, 2021 1.27 [1.02; 1.58]
ConPlas-19, 2020 0.89 [0.43; 1.86]
Dongsheng Wang, 2020 0.91 [0.02; 47.31]
GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
Krolewiecki, 2020 1.00 [0.03; 31.59]
Lou Y, 2020 2.25 [0.38; 13.47]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
NCT04542694, 2020 6.15 [0.30; 124.49]
Pandit, 2021 0.95 [0.02; 50.33]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
Ruzhentsova T, 2020 2.06 [0.09; 46.40]
Sadeghi , 2020 1.00 [0.02; 51.94]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13]
Talaschian, 2021 7.93 [0.37; 171.38]
Udwadia, 2020 1.03 [0.02; 52.48]
Veiga, 2021 1.66 [0.60; 4.59]
Yakoot, 2020 1.02 [0.02; 52.72]
1.14 [1.01 ; 1.30 ] Cao, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, CONCOR-1, 2021, ConPlas-19, 2020, Dongsheng Wang, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Krolewiecki, 2020, Lou Y, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Raman, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, Ruzhentsova T, 2020, Sadeghi , 2020, Sekine (PLACOVID), 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Udwadia, 2020, Veiga, 2021, Yakoot, 2020 28 0% 8,734 moderate low superinfectiondetailed results Rahmani, 2020 0.18 [0.02; 1.59]
0.18 [0.02 ; 1.59 ] Rahmani, 2020 1 0% 66 NA not evaluable acute kidney injury detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18]
1.18 [0.44 ; 3.18 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78]
COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08]
Dongsheng Wang, 2020 9.64 [2.76; 33.75]
GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
Kirenga, 2021 1.13 [0.50; 2.58]
Krolewiecki, 2020 1.53 [0.42; 5.58]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
NCT04542694, 2020 1.00 [0.54; 1.85]
Pandit, 2021 1.68 [0.47; 5.97]
Raman, 2021 1.36 [0.56; 3.30]
RECOVERY, 2020 1.36 [0.98; 1.90]
Ruzhentsova T, 2020 1.90 [0.96; 3.80]
Sakoulas, 2020 1.00 [0.02; 53.46]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shu, 2020 2.48 [0.05; 132.54]
Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87]
Udwadia, 2020 6.36 [2.43; 16.65]
Veiga, 2021 1.65 [0.81; 3.37]
1.53 [1.26 ; 1.85 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, Dongsheng Wang, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Kirenga, 2021, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Raman, 2021, RECOVERY, 2020, Ruzhentsova T, 2020, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shu, 2020, Soin AS (COVINTOC), 2021, Udwadia, 2020, Veiga, 2021 21 44% 8,592 moderate critical arrhythmiadetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69]
RECOVERY (AZI, Horby), 2020 0.90 [0.71; 1.15]
Sekhavati, 2020 0.98 [0.02; 50.38]
0.91 [0.72 ; 1.15 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, RECOVERY (AZI, Horby), 2020, Sekhavati, 2020 3 0% 8,290 moderate not evaluable elevated liver enzymesdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64]
3.48 [1.40 ; 8.64 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable long QTdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50]
COALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43]
2.39 [0.24 ; 23.87 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 80% 613 moderate not evaluable renal impairmentdetailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86]
COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11]
1.43 [1.00 ; 2.05 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 0% 770 moderate not evaluable Thromboembolic eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55]
0.89 [0.31 ; 2.55 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-26 19:41 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290